SynthesisNeurology2017
Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation.
Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph
Synthesis in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 7 pooled it
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 7 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Anticoagulation versus no anticoagulation after intracranial hemorrhage in patients with atrial fibrillation: an updated systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Antithrombotic treatment after stroke due to intracerebral haemorrhage.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Meta-Analysis of Oral Anticoagulants and Adverse Outcomes in Atrial Fibrillation Patients After Intracranial Hemorrhage.Frontiers in cardiovascular medicine · 2022Pooled it
- Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis.BMJ open · 2018Pooled it
- Antithrombotic Therapy After Intracerebral Hemorrhage: Real-World Evidence for In-Hospital Resumption.CNS neuroscience & therapeutics · 2026Article
- Personalized Medicine, Public Health and Patient-Centred Aspects in the Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF) Project.Thrombosis and haemostasis · 2026Article
- Clinical Characteristics in Adult Congenital Heart Disease Patients With Acute Stroke - A Retrospective Analysis.Circulation reports · 2025Article
- GRAPE: graph-regularized protein language modeling unlocks TCR-epitope binding specificity.Briefings in bioinformatics · 2025Article
- Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial.Thrombosis and haemostasis · 2025Article
- Article
- GTE: a graph learning framework for prediction of T-cell receptors and epitopes binding specificity.Briefings in bioinformatics · 2024Article
- Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage.European journal of medical research · 2024Review
- Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation.Journal of thrombosis and thrombolysis · 2023Article
- Management of oral anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis.Frontiers in neuroscience · 2023Review
- Cerebral small vessel disease and intracranial bleeding risk: Prognostic and practical significance.International journal of stroke : official journal of the International Stroke Society · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Eleni KorompokiFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Filippos T FilippidisFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Peter B NielsenFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Angela Del GiudiceFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Gregory Y H LipFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Joji B KuramatsuFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Hagen B HuttnerFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Jiming FangFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Sam SchulmanFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Joan Martí-FàbregasFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Celine S GathierFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Anand ViswanathanFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Alessandro BiffiFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Daniela PoliFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Christian WeimarFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Uwe MalzahnFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Peter HeuschmannFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany.
Roland VeltkampFrom the Division of Brain Sciences (E.K., A.D.G., R.V.), Department of Stroke Medicine, and Department of Primary Care and Public Health (F.T.F.), Imperial College, London, UK; Aalborg Thrombosis Research Unit (P.B.N., G.Y.H.L.), Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; Institute of Cardiovascular Sciences (G.Y.H.L.), University of Birmingham, UK; Department of Neurology (J.B.K., H.B.H.), University of Erlangen-Nuremberg, Erlangen, Germany; Institute for Clinical Evaluative Sciences (J.F.), Toronto; Thrombosis and Atherosclerosis Research Institute (S.S.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Stroke Unit (J.M.-F.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Department of Neurology and Neurosurgery (C.S.G.), Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Department of Neurology (A.V., A.B.), Massachusetts General Hospital, Harvard Medical School, Boston; Thrombosis Center (D.P.), Careggi Hospital, Florence, Italy; Department of Neurology (C.W.), University Hospital of Duisburg-Essen, Essen; Clinical Trial Center Würzburg (U.M., P.H.), University Hospital Würzburg; and Institute of Clinical Epidemiology and Biometry (P.H.), Comprehensive Heart Failure Center, University Würzburg, Germany. r.veltkamp@imperial.ac.uk.
Aalborg University · DK
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up.
methodsA comprehensive literature search including MEDLINE, EMBASE, Cochrane library, clinical trials registry was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We considered studies capturing outcome events (ICH recurrence and IS) for ≥3 months and treatment exposure to vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). Corresponding authors provided aggregate data for IS and ICH recurrence rate between 6 weeks after the event and 1 year of follow-up for each treatment exposure. Meta-analyses of pooled rate ratios (RRs) were conducted with the inverse variance method.
resultsSeventeen articles met inclusion criteria. Seven observational studies enrolling 2,452 patients were included in the meta-analysis. Pooled RR estimates for IS were lower for VKAs compared to APAs (RR = 0.45, 95% confidence interval [CI] 0.27-0.74,
conclusionsIn observational studies, anticoagulation with VKA is associated with a lower rate of IS than APA or no-ATM without increasing ICH recurrence significantly. A randomized controlled trial is needed to determine the net clinical benefit of anticoagulation in ICH survivors with AF.
Indexed as
Atrial FibrillationBrain IschemiaFibrinolytic AgentsHumansIntracranial HemorrhagesPlatelet Aggregation InhibitorsStrokeVitamin KFibrinolytic AgentsPlatelet Aggregation InhibitorsVitamin K
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.